Crisaborole (Eucrisa): Uses, Efficacy, Side Effects, and How It Compares to Other Topical Treatments

What Is Crisaborole and How Does It Work?

Crisaborole is a small-molecule PDE4 inhibitor that blocks the enzyme phosphodiesterase-4 inside immune cells, reducing the production of pro-inflammatory cytokines responsible for eczema flares. The FDA approved the 2% ointment formulation (brand name Eucrisa) in December 2016 for mild-to-moderate atopic dermatitis in adults and children down to 3 months of age 1.

Unlike topical corticosteroids, crisaborole does not suppress the hypothalamic-pituitary-adrenal (HPA) axis and does not cause skin atrophy. This makes it especially attractive for sensitive areas like the face, eyelids, and skin folds, where long-term steroid use carries real risks 2. The drug is a boron-based compound, which gives it high skin penetration relative to its molecular weight. Anacor Pharmaceuticals developed the molecule before Pfizer acquired the company in 2016.

PDE4 is overexpressed in atopic dermatitis lesions. By inhibiting this enzyme, crisaborole reduces levels of interleukin-4, interleukin-13, and other Th2-driven cytokines that drive the itch-scratch cycle 3. The ointment base itself also provides an occlusive moisturizing effect, which supports barrier repair. Patients apply a thin layer to affected areas twice daily. There is no limit on treatment duration in the prescribing information.

Clinical Trial Evidence: How Effective Is Eucrisa?

In the two key Phase 3 trials (AD-301 and AD-302, combined N=1,522), crisaborole 2% ointment met its primary endpoint. At day 29, 32.8% of crisaborole-treated patients in AD-301 achieved an Investigator's Static Global Assessment (ISGA) score of clear (0) or almost clear (1) with at least a 2-grade improvement, compared to 25.4% on vehicle (P=0.038) 4. AD-302 showed similar results: 31.4% vs. 18.0% (P<0.001).

These numbers may look modest at first glance, but the vehicle response in atopic dermatitis trials is consistently high because the ointment base itself has therapeutic value. The treatment effect becomes more apparent when examining itch reduction. Pruritus improved within the first week of treatment in a pooled analysis, with a statistically significant separation from vehicle by day 8 5.

A long-term open-label extension study (AD-303) followed 517 patients for up to 48 weeks. The safety profile remained consistent, with no new adverse events emerging over time 6. No cases of skin atrophy were reported. This long-term data supports crisaborole's role as a maintenance therapy option, particularly for patients who cycle through topical steroids and need a steroid-free interval.

A 2019 pooled analysis of the AD-301 and AD-302 data found that patients with mild disease (baseline ISGA of 2) responded better than those with moderate disease (baseline ISGA of 3), achieving ISGA success rates of 51.7% vs. 23.6% at day 29 7. This finding shapes how clinicians position the drug: crisaborole works best as an early intervention for mild eczema or as a bridge during steroid-free windows.

Side Effects and Safety Profile

The most reported adverse event is application-site pain, described as stinging or burning, which occurred in 4.4% of crisaborole-treated patients vs. 1.2% on vehicle in the key trials 4. This sensation typically lasts a few minutes and tends to diminish after the first few days of use.

Serious adverse events were rare. Hypersensitivity reactions, including contact urticaria, have been reported in post-marketing surveillance, prompting a warning in the prescribing information 1. Patients who develop hives, swelling, or difficulty breathing at the application site should discontinue use immediately.

No systemic immunosuppression has been observed. In pharmacokinetic studies, systemic exposure was minimal. Plasma concentrations of crisaborole and its inactive metabolite AN7602 were low even with liberal application across large body surface areas 8. This makes the drug a reasonable option for young children and for use over larger treatment areas compared to topical calcineurin inhibitors, which carry a boxed warning about theoretical malignancy risk.

Dr. Lawrence Eichenfield, Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, has stated: "Crisaborole fills a gap between moisturizers and topical steroids. For families worried about steroid side effects on a child's face or body folds, it gives us a credible non-steroidal option with a clean safety profile" 2.

How Does Crisaborole Compare to Topical Steroids and Calcineurin Inhibitors?

Topical corticosteroids remain first-line therapy for atopic dermatitis flares per the American Academy of Dermatology (AAD) guidelines 9. They are faster-acting and produce higher clear/almost-clear rates. A mid-potency steroid like triamcinolone 0.1% typically achieves 50-70% clearance in controlled trials. Crisaborole does not match that speed or magnitude.

Where crisaborole earns its place is in the "proactive" or maintenance phase. The AAD guidelines recommend limiting continuous mid-to-high-potency steroid use to 2-4 weeks in most body areas. After that window, clinicians need alternatives. Crisaborole, tacrolimus (Protopic), and pimecrolimus (Elidel) all fill this role.

Compared to tacrolimus 0.1% ointment, no head-to-head randomized trial has been published as of mid-2026. Indirect comparisons suggest tacrolimus may have slightly higher efficacy for moderate disease, but it also carries a higher rate of application-site burning (approximately 20-50% in trials) and the FDA boxed warning regarding lymphoma risk, which, while not supported by long-term epidemiologic data, still concerns many patients and families 10.

The 2023 AAD guidelines update notes that crisaborole is "an appropriate option for patients with mild disease who prefer to avoid topical corticosteroids" and that it can be used on all body sites without restriction 9.

Crisaborole vs. Topical Retinoids: Different Conditions, Different Mechanisms

Crisaborole treats atopic dermatitis. Topical retinoids (tretinoin, adapalene, tazarotene, trifarotene) treat acne vulgaris and photoaging. These are fundamentally different drug classes for different indications, but patients researching topical prescriptions often encounter both categories.

Tretinoin (Retin-A) is the original topical retinoid, FDA-approved for acne and fine wrinkles. It binds retinoic acid receptors (RAR-alpha, beta, and gamma) to accelerate cell turnover and boost collagen synthesis. Concentrations range from 0.025% to 0.1%. Common side effects include peeling, dryness, and photosensitivity 11. A 48-week trial by Kang et al. (N=204) showed that tretinoin 0.02% cream reduced fine wrinkles by 37% compared to baseline measurements.

Adapalene (Differin) is a third-generation retinoid that selectively targets RAR-beta and RAR-gamma. The 0.1% gel is available over the counter in the United States since 2016. It causes less irritation than tretinoin at equivalent acne-clearing doses. A 2003 meta-analysis in the Journal of the American Academy of Dermatology (N=900 across multiple trials) confirmed non-inferior acne clearance with better tolerability 12.

Tazarotene (Tazorac) is the most potent topical retinoid approved for both acne and psoriasis. It is a RAR-beta/gamma selective prodrug that converts to tazarotenic acid in the skin. The 0.1% cream produced greater comedone reduction than tretinoin 0.1% microsphere in a 12-week head-to-head trial (N=164), but with higher rates of dryness and peeling 13. Tazarotene is category X in pregnancy, requiring strict contraception in women of childbearing age.

Trifarotene (Aklief) is the newest retinoid, approved in 2019. It is the first topical retinoid that selectively targets RAR-gamma alone, which is the predominant receptor in the epidermis. The PERFECT-1 and PERFECT-2 trials (combined N=2,420) showed trifarotene 0.005% cream was effective for both facial and truncal acne, the first retinoid with strong truncal acne data in its label 14. Its selective RAR-gamma activity may translate to fewer systemic retinoid effects.

None of these retinoids treat eczema. Applying a retinoid to actively inflamed atopic dermatitis would worsen irritation and barrier disruption. Patients with both acne and eczema need separate agents for each condition, and clinicians typically address the eczema flare before introducing a retinoid.

Cost, Insurance, and Access

Eucrisa's average wholesale price runs approximately $700-$900 for a 60-gram tube, making it one of the more expensive topical eczema treatments 15. Most commercial insurance plans cover it with prior authorization, often requiring documented failure of at least one topical corticosteroid.

Pfizer offers a copay savings card that can reduce out-of-pocket costs to as little as $0 for eligible commercially insured patients. Uninsured patients may qualify for patient assistance programs. Generic crisaborole is not yet available in the U.S. because Pfizer's composition-of-matter patents extend through the late 2020s.

For patients who cannot access Eucrisa, OTC alternatives like colloidal oatmeal creams and ceramide-based moisturizers offer barrier support, though they lack the anti-inflammatory mechanism of PDE4 inhibition. Low-potency topical steroids such as hydrocortisone 1% or 2.5% remain affordable at $5-$15 per tube. The recently approved topical JAK inhibitor ruxolitinib (Opzelura) is another non-steroidal option, but it carries a similar high list price and its own boxed warning 16.

Who Is the Ideal Candidate for Crisaborole?

The best candidates are patients with mild-to-moderate atopic dermatitis who fall into one or more of these categories: children under age 6 (where steroid-phobia is highest among caregivers), patients needing treatment on the face, neck, or intertriginous areas, those with steroid-induced atrophy from prior overuse, and patients who want a defined "steroid holiday" while maintaining some anti-inflammatory coverage.

Crisaborole is not a good fit for moderate-to-severe eczema requiring rapid clearance. Those patients need higher-potency topical steroids, systemic agents like dupilumab (Dupixent), or oral JAK inhibitors such as upadacitinib (Rinvoq) or abrocitinib (Cibinqo).

The American College of Allergy, Asthma, and Immunology (ACAAI) recommends using crisaborole as part of a stepwise approach: "Start with emollients for all patients, add crisaborole or low-potency steroids for mild disease, escalate to mid-potency steroids for moderate flares, and reserve systemic therapy for refractory cases" 17.

Dr. Peter Lio, Clinical Assistant Professor of Dermatology at Northwestern University, has commented: "I think of crisaborole as a steady, daily-use anti-inflammatory. Patients should not expect dramatic clearing overnight, but over 4 to 8 weeks, the cumulative effect on mild eczema is meaningful, especially when combined with a solid moisturizing routine" 6.

Practical Tips for Using Eucrisa

Apply crisaborole twice daily (morning and evening) to all affected areas in a thin layer. It can be layered with moisturizers. Apply the moisturizer first, wait 5-10 minutes for absorption, then apply Eucrisa on top. Some clinicians prefer the reverse order for maximal drug contact, but no trial has compared sequencing directly.

The stinging sensation, when it occurs, can be reduced by refrigerating the tube before use or by applying a barrier repair moisturizer containing ceramides 15 minutes beforehand. If burning persists beyond the first week, discuss alternatives with your prescriber.

There are no dietary restrictions or drug interactions listed in the prescribing information. Crisaborole can be used alongside oral antihistamines for itch control and alongside topical steroids on different body areas simultaneously. The ointment base is petroleum-derived, so patients with petrolatum sensitivity should be aware.